Foldax is a clinical-stage company that has developed the world’s first synthetic polymer aortic and mitral heart valves. The company is delivering non-thrombogenic heart valves at dramatically lower costs to existing artificial or tissue valves.
Year Founded: 2013
Key Executives:
• Gregory Casciaro, CEO
• Ken Charhut, Chairman
Location: Salt Lake City, UT
Website: https://foldax.com/
Company Status: Private
Foldax®, Inc., a leader in the development of innovative, polymer heart valves, today announced that its...
Read moreFoldax® Inc., a pioneer in the development of innovative, polymer heart valves, today announced a manufacturing...
Read moreFoldax announced completion of enrollment in the Indian clinical trial of the TRIA™ polymer surgical mitral...
Read moreFoldax announced that the first 30 patients have been treated outside of the U.S., in the...
Read moreFoldax announced that it has executed an agreement with Australia’s national science agency, CSIRO, for full...
Read moreFoldax Inc. announced that medtech veteran Gregory D. Casciaro has been named Chief Executive Officer of...
Read moreFoldax announced that the first patients have been enrolled in the Drugs Controller General of India...
Read moreFoldax has announced the presentation of results from the first animal study of its transcatheter valve...
Read moreFoldax announced publication of the first clinical results for its TRIA™ biopolymer heart valve - the...
Read moreFoldax® announced completion of enrollment in the U.S. early feasibility study of the TRIA™ surgical aortic...
Read moreFoldax announced the successful first-in-human use of its biopolymer Tria™ heart valve in surgically replacing a...
Read moreFoldax is looking to reinvent every aspect of the heart valve—from material, to design, to manufacturing....
Read more